We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Mutation Causes Devastating Mitochondrial Diseases

By LabMedica International staff writers
Posted on 19 Sep 2013
Print article
Image: Histology of mitochondrial encephalomyopathy with ragged red fibers (Photo courtesy of Dr. K.K. Abu-Amero).
Image: Histology of mitochondrial encephalomyopathy with ragged red fibers (Photo courtesy of Dr. K.K. Abu-Amero).
A novel disease gene has been identified in which mutations cause rare but devastating genetic diseases known as mitochondrial disorder.

Mitochondrial diseases are caused by mutations in either mitochondrial DNA or in genes in the nucleus that encode for proteins that function in the mitochondria.

Scientists at the Loyola University Stritch School of Medicine (Maywood, IL, USA) and their multi-institute collaborators performed a battery of genetic tests to identify a nuclear gene that encodes for a protein called F-Box and Leucine-Rich Repeat Protein 4 (FBXL4).

They found that mutations of this FBXL4 gene lead to either truncated or altered forms of the protein. This results in cells having less mitochondrial DNA, decreased mitochondrial membrane potential and a faulty process in cell metabolism called oxidative phosphorylation. The study also proved that the FBXL4 protein is located exclusively in mitochondria, which was previously unrecognized.

The team used high-performance computer cluster to analyze billions of DNA sequences to identify the gene mutation in a child and her parents. The scientists then reached out to other collaborators to see if any of their patients also had the FBXL4 mutation. Eight additional affected children in six unrelated families were found to also have disease-causing mutations in this gene.

Biochemical assays performed on clinical basis in muscle and/or fibroblasts obtained from several subjects confirmed the deleterious effect of FBXL4 mutations on mitochondrial bioenergetics. Muscle homogenates or isolated mitochondria from subjects with FBXL4 mutations showed variably decreased activity of mitochondrial respiratory chain complexes.

The authors concluded that they provided evidence that recessive FBXL4 mutations are responsible for severe, infantile-onset mitochondrial encephalomyopathy. A child can inherit a mitochondrial disease either from the mother alone or from both parents carrying mutations in the same nuclear gene. Mitochondrial diseases affect between 1 in 4,000 and 1 in 5,000 people. The study was published on August 29, 2013, in the American Journal of Human Genetics.

Related Links:
Loyola University Stritch School of Medicine

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.